New pill could ease rare skin disease
NCT ID NCT07090889
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an oral drug called KM-023 for Olmsted Syndrome, a rare genetic condition causing painful, thick skin on the palms and soles. First, healthy volunteers will receive single or multiple doses to check safety and how the body handles the drug. Then, patients with Olmsted Syndrome will take the drug twice daily for 12 weeks to see if it reduces skin thickening and lesions. The study is small and focused on safety, not yet proof of a cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KM-023 (oral solution)
- What this could lead to
- If this early trial shows promise, it could point toward a treatment that reduces painful skin thickening and lesions in Olmsted Syndrome.
- What could go wrong
- This is a very early Phase 1 study with only 64 participants. The main goal is safety, not proof of effectiveness. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLMSTED SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biotrial
RECRUITINGRennes, France
-
Northwestern University, Department of Dermatology
RECRUITINGChicago, Illinois, 60611, United States
-
Paris Descartes Necker Cochin, Hôpital Necker-Enfants Malades Bat Imagine RDC
RECRUITINGParis, France
-
Royal London Hospital
RECRUITINGLondon, United Kingdom